Vasomune Therapeutics to Showcase Research at Leading Pulmonary Conference

Vasomune Therapeutics to Present Late-Breaking Research on AV-001 at the 2025 American Thoracic Society International Conference Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to address diseases driven by vascular dysfunction, today announced its participation in the 2025…

Read MoreVasomune Therapeutics to Showcase Research at Leading Pulmonary Conference

Harmony Biosciences Posts Strong Q1 2025 Results, Highlights Pipeline Progress and 2025 Outlook

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported robust financial and operational results for the first quarter of 2025, underscoring the company’s continued momentum and strategic focus on advancing its late-stage pipeline while reaffirming full-year revenue guidance. The company achieved a…

Read MoreHarmony Biosciences Posts Strong Q1 2025 Results, Highlights Pipeline Progress and 2025 Outlook

Fresenius Medical Care Delivers Robust Organic Growth in Revenue and Income in Q1 2025

Fresenius Medical Care Achieves Strong Start to 2025 with Solid Organic Growth and Improved Profitability Across Segments Fresenius Medical Care, the world’s leading provider of products and services for individuals with chronic kidney failure, began 2025 with a strong operational…

Read MoreFresenius Medical Care Delivers Robust Organic Growth in Revenue and Income in Q1 2025

Modivcare Unveils Leadership Transitions Amid Strategic Evolution of Business Model

Modivcare Announces Executive Leadership Transitions Amid Strategic Business Model Evolution Modivcare Inc. (Nasdaq: MODV), a leading technology-enabled healthcare services company focused on delivering supportive care solutions that address social determinants of health, today announced the planned departures of two key…

Read MoreModivcare Unveils Leadership Transitions Amid Strategic Evolution of Business Model

TAE Life Sciences Partners with Ohio State University to Drive Innovation in Boron-Based Cancer Therapies

TAE Life Sciences and Ohio State Forge Landmark Partnership to Advance Boron-Based Precision Cancer Therapies In a significant leap forward for precision oncology, TAE Life Sciences (TLS), a pioneer in accelerator-based cancer treatment technologies, has announced a transformative collaboration with…

Read MoreTAE Life Sciences Partners with Ohio State University to Drive Innovation in Boron-Based Cancer Therapies